% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Becker:274346,
      author       = {J. Becker$^*$ and A. J. Beer and V. K. DeTemple and T.
                      Eigentler and M. Flaig and T. Gambichler and S. Grabbe and
                      U. Höller and B. Klumpp and S. Lang and C. Pföhler and C.
                      Posch and V. Prasad and P. Schlattmann and S.
                      Schneider-Burrus and J. Ter-Nedden and P. Terheyden and K.
                      Thoms and D. Vordermark and S. Ugurel},
      title        = {{S}2k {G}uideline - {M}erkel cell carcinoma ({MCC},
                      neuroendocrine carcinoma of the skin) - {U}pdate
                      2022.[{S}2k-{L}eitlinie - {M}erkelzellkarzinom - {U}pdate
                      2022].},
      journal      = {Journal der Deutschen Dermatologischen Gesellschaft},
      volume       = {21},
      number       = {3},
      issn         = {1610-0379},
      address      = {Berlin},
      publisher    = {Wiley-Blackwell},
      reportid     = {DKFZ-2023-00548},
      pages        = {305 - 320},
      year         = {2023},
      note         = {german: doi: $10.1111/ddg.14930_g$},
      abstract     = {Merkel cell carcinoma (MCC, ICD-O M8247/3) is a rare,
                      malignant, primary skin tumor with epithelial and
                      neuroendocrine differentiation. The tumor cells share many
                      morphologic, immunohistochemical, and ultrastructural
                      features with cutaneous Merkel cells. Nevertheless, the cell
                      of origin of MCC is unclear. MCC appears clinically as a
                      reddish to purple spherical tumor with a smooth, shiny
                      surface and a soft to turgid, elastic consistency, usually
                      showing rapid growth. Spontaneous and often complete
                      regressions of the tumor are observed. These likely
                      immunologically-mediated regressions explain the cases in
                      which only lymph node or distant metastases are found at the
                      time of initial diagnosis and why the tumor responds very
                      well to immunomodulatory therapies even at advanced stages.
                      Due to its aggressiveness, the usually given indication for
                      sentinel lymph node biopsy, the indication of adjuvant
                      therapies to be evaluated, as well as the complexity of the
                      necessary diagnostics, clinical management should already be
                      determined by an interdisciplinary tumor board at the time
                      of initial diagnosis.},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36929552},
      doi          = {10.1111/ddg.14930},
      url          = {https://inrepo02.dkfz.de/record/274346},
}